Curated News
By: NewsRamp Editorial Staff
May 29, 2024

Global Retinoblastoma Treatment Market to Reach $4.20 Billion by 2034, Iovance Biotherapeutics Receives FDA Approval for Lifileucel

Reddit Discuss on RedditDiscuss on Substack Discuss on Substack
Source News Release

TLDR

  • Investing in retinoblastoma treatment market expected to reach $4.20 billion by 2034 may provide a competitive advantage in the growing healthcare sector.
  • The FDA granted accelerated approval to Iovance Biotherapeutics’ lifileucel for inoperable or metastatic melanoma, using a patient’s unique T cells to fight cancer.
  • Developing necroptosis cancer therapies can make tomorrow better by providing more efficient treatments with fewer side effects, ultimately improving cancer patients’ quality of life.
  • The recent approval of TIL cell therapy and the development of necroptosis therapies for retinoblastoma and uveal melanoma demonstrate exciting advancements in cancer treatment technology.

Impact - Why it Matters

The news is significant as it highlights the increasing market size for retinoblastoma treatment and the development of innovative therapies for ocular cancers. The FDA approval for lifileucel indicates progress in advanced treatments for melanoma, offering hope for patients with inoperable or metastatic melanoma. The collaboration between Oncotelic Therapeutics and Mosaic ImmunoEngineering demonstrates a commitment to developing cutting-edge therapies for retinoblastoma and uveal melanoma, potentially improving treatment outcomes and quality of life for patients.

Summary

The global retinoblastoma treatment market is projected to reach $4.20 billion by 2034, driven by factors such as rising incidence of retinoblastoma, early diagnosis and treatment, increasing healthcare expenditure, and government initiatives. Iovance Biotherapeutics has received FDA approval for lifileucel (Amtagvi) to treat inoperable or metastatic melanoma, making it the first one-time tumor-infiltrating lymphocyte (TIL) therapy approved for solid tumors. Oncotelic Therapeutics and Mosaic ImmunoEngineering are collaborating to develop necroptosis therapies for ocular cancers, including retinoblastoma and uveal melanoma. Mosaic will acquire the rights to Oncotelic's clinical-stage necroptosis cancer therapies, disrupting tumor blood flow and triggering a potent anti-cancer immune response.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Global Retinoblastoma Treatment Market to Reach $4.20 Billion by 2034, Iovance Biotherapeutics Receives FDA Approval for Lifileucel

blockchain registration record for the source press release.